FDA Warning Letter to HydraMed Cites Misleading Compounded GLP-1 Labels and "FDA-Approved Pharmacy" Claim
On June 8, 2026, FDA issued a warning letter to HydraMed after a March 2026 review of hydramed.com, which offers compounded semaglutide and tirzepatide products. FDA says product images identify "HydraMed" on the label, "suggesting HydraMed is the compounder of those drugs when in fact it is not," and that the site’s claim that products come from an "FDA-approved pharmacy" is "false and misleading" because FDA does not approve or license compounding pharmacies. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗